+ Follow ATORVASTATIN Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1376681
[Title] => Paano pinabababa ang kolesterol?
[Summary] => SI Linda ay nag-aalala dahil ang resulta ng kolesterol niya ay 273 mg/dl. Sobra ito ng 73 points sa normal na 200 mg/dl. Kahit wala siyang nararamdaman, natatakot si Linda na baka atakehin siya sa puso. Ano ang dapat niyang gawin?
[DatePublished] => 2014-10-05 00:00:00
[ColumnID] => 134738
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => Punto Mo
[SectionUrl] => punto-mo
[URL] =>
)
[1] => Array
(
[ArticleID] => 1338997
[Title] => Mataas ang cholesterol
[Summary] => NAPAKARAMING pasyenteng mahihirap ang nareresetahan ng mamahaling gamot sa cholesterol. Ang tawag dito ay Statins at nagkakahalaga ito ng P20–P60 bawat tableta. Ang mga kilalang Statins ay ang Simvastatin, Atorvastatin, at iba pa.
[DatePublished] => 2014-06-26 00:00:00
[ColumnID] => 134020
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => PSN Opinyon
[SectionUrl] => opinyon
[URL] =>
)
[2] => Array
(
[ArticleID] => 584585
[Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
[Summary] => Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
[DatePublished] => 2010-06-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 478231
[Title] => When stroke strikes
[Summary] => MANILA, Philippines – Strokes kill about five million people each year and is considered as the second leading cause of death worldwide. At least 15 million patients have non-fatal strokes annually, and about a third is significantly disabled as a consequence. In the Philippines, it is one of the leading causes of death together with other vascular diseases.
[DatePublished] => 2009-06-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 477593
[Title] => When stroke strikes
[Summary] => MANILA, Philippines – Strokes kill about five million people each year and is considered as the second leading cause of death worldwide. At least 15 million patients have non-fatal strokes annually, and about a third is significantly disabled as a consequence.
[DatePublished] => 2009-06-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[5] => Array
(
[ArticleID] => 476128
[Title] => Local pharma firm aims to boost market foothold
[Summary] => Cebu, Philippines - Even if the industry seems to be having a slower growth rate due to the present global economic crisis, Filipino pharmaceutical company Innogen Pharma Group continues to see growth areas in the market this year.
[DatePublished] => 2009-06-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Business
[SectionUrl] => cebu-business
[URL] =>
)
[6] => Array
(
[ArticleID] => 32877
[Title] => Trial shows benefits of atorvastatin calcium
[Summary] =>
[DatePublished] => 2007-12-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 25359
[Title] => Statin pretreatment reduces contrast nephropathy in PCI
[Summary] =>
[DatePublished] => 2007-11-04 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[8] => Array
(
[ArticleID] => 336785
[Title] => Medicinal calcium said to treat kidney failure
[Summary] => An estimated 20 million Americans suffer from chronic kidney disease (CKD). In people with CKD, kidneys cannot effectively filter the toxins from the blood, which can lead to kidney failure.
[DatePublished] => 2006-05-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[9] => Array
(
[ArticleID] => 264972
[Title] => Who says only toothpaste stops plaque?
[Summary] => The cholesterol-lowering atorvastatin calcium has been shown to stop progression of plaque build-up in arteries. Patients taking atorvastatin experienced a significant reduction in the progression of atherosclerosis, or hardening of the arteries, compared to patients who received pravastatin, according to new data published in the Journal of the American Medical Association.
[DatePublished] => 2004-09-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
ATORVASTATIN
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1376681
[Title] => Paano pinabababa ang kolesterol?
[Summary] => SI Linda ay nag-aalala dahil ang resulta ng kolesterol niya ay 273 mg/dl. Sobra ito ng 73 points sa normal na 200 mg/dl. Kahit wala siyang nararamdaman, natatakot si Linda na baka atakehin siya sa puso. Ano ang dapat niyang gawin?
[DatePublished] => 2014-10-05 00:00:00
[ColumnID] => 134738
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => Punto Mo
[SectionUrl] => punto-mo
[URL] =>
)
[1] => Array
(
[ArticleID] => 1338997
[Title] => Mataas ang cholesterol
[Summary] => NAPAKARAMING pasyenteng mahihirap ang nareresetahan ng mamahaling gamot sa cholesterol. Ang tawag dito ay Statins at nagkakahalaga ito ng P20–P60 bawat tableta. Ang mga kilalang Statins ay ang Simvastatin, Atorvastatin, at iba pa.
[DatePublished] => 2014-06-26 00:00:00
[ColumnID] => 134020
[Focus] => 0
[AuthorID] => 1805275
[AuthorName] => Dr. Willie T. Ong
[SectionName] => PSN Opinyon
[SectionUrl] => opinyon
[URL] =>
)
[2] => Array
(
[ArticleID] => 584585
[Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
[Summary] => Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
[DatePublished] => 2010-06-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 478231
[Title] => When stroke strikes
[Summary] => MANILA, Philippines – Strokes kill about five million people each year and is considered as the second leading cause of death worldwide. At least 15 million patients have non-fatal strokes annually, and about a third is significantly disabled as a consequence. In the Philippines, it is one of the leading causes of death together with other vascular diseases.
[DatePublished] => 2009-06-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 477593
[Title] => When stroke strikes
[Summary] => MANILA, Philippines – Strokes kill about five million people each year and is considered as the second leading cause of death worldwide. At least 15 million patients have non-fatal strokes annually, and about a third is significantly disabled as a consequence.
[DatePublished] => 2009-06-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[5] => Array
(
[ArticleID] => 476128
[Title] => Local pharma firm aims to boost market foothold
[Summary] => Cebu, Philippines - Even if the industry seems to be having a slower growth rate due to the present global economic crisis, Filipino pharmaceutical company Innogen Pharma Group continues to see growth areas in the market this year.
[DatePublished] => 2009-06-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Freeman Cebu Business
[SectionUrl] => cebu-business
[URL] =>
)
[6] => Array
(
[ArticleID] => 32877
[Title] => Trial shows benefits of atorvastatin calcium
[Summary] =>
[DatePublished] => 2007-12-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 25359
[Title] => Statin pretreatment reduces contrast nephropathy in PCI
[Summary] =>
[DatePublished] => 2007-11-04 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[8] => Array
(
[ArticleID] => 336785
[Title] => Medicinal calcium said to treat kidney failure
[Summary] => An estimated 20 million Americans suffer from chronic kidney disease (CKD). In people with CKD, kidneys cannot effectively filter the toxins from the blood, which can lead to kidney failure.
[DatePublished] => 2006-05-15 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[9] => Array
(
[ArticleID] => 264972
[Title] => Who says only toothpaste stops plaque?
[Summary] => The cholesterol-lowering atorvastatin calcium has been shown to stop progression of plaque build-up in arteries. Patients taking atorvastatin experienced a significant reduction in the progression of atherosclerosis, or hardening of the arteries, compared to patients who received pravastatin, according to new data published in the Journal of the American Medical Association.
[DatePublished] => 2004-09-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
December 13, 2007 - 12:00am
September 16, 2004 - 12:00am
